Multimodal Liquid Biopsy for Early Cancer Detection: From Methylation to Single-Molecule Sequencing

Thursday, January 28, 2027 at 2:10 PM to 2:40 PM · 30 min. (Europe/London)
Cancer Diagnostics Stage
Day 2 - Thursday 28th January
CancerDiagnosticsLiquid BiopsyMulti-Omics

Information

  • Multi-cancer Early Detection tests are likely to be useful in certain well-defined high-risk populations. 
  • However, first-generation tests have major drawbacks, not least their high cost, lack of sensitivity and high false positive rate, esp. in asymptomatic population screening. 
  • These drawbacks call for technical innovations that are no longer solely based on wet-lab IP, but on the systematic use of AI-based algorithms for calling differences between normal, noise and cancer signals. 
  • AI-informed multi-modal analysis of circulating tumour DNA is a promising avenue that avoids trading increased sensitivity against specificity. 
  • As more of MCEDs enter the market, rigorous evaluation of their clinical utility through expensive and slow randomised controlled studies will be increasingly replaced by bench-marking exercises and possibly by linking early detection to early intervention studies, thus allowing for faster and more effective innovation cycles.